Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient‐Reported Outcomes Measurement Information System Short Forms in S... by Patricia Katz, Sofia Pedro, Evo Alemao, Jinoos Yazdany, Maria Dall'Era, Laura Trupin, Stephanie Rush, Kaleb Michaud

Get full text

Understanding the Association between Red Blood Cell Transfusion Utilization and Humanistic and Economic Burden in Patients with β-Thalassemia from the Patients’ Perspective by Russell L. Knoth, Shaloo Gupta, Kacper Perkowski, Halley Costantino, Brian Inyart, Lauren Ashka, Kelly Clapp

Get full text

Has the COVID-19 Pandemic Led to a Switch in the Volatility of Biopharmaceutical Companies? by Adriana AnaMaria Davidescu, Eduard Mihai Manta, Oana Mihaela Vacaru (Boita), Mihaela Gruiescu, Razvan Gabriel Hapau, Paul Laurentiu Baranga

“…Analyzing the contagion effects makes it even more relevant to analyze the stock market response of four leading pharmaceutical companies that either developed vaccines against COVID-19 or drugs that help to fight the virus, namely, Pfizer, AbbVie Inc., Sanofi, and Bristol Myers Squibb. The analysis considers two periods, before and during the COVID-19 crisis, and considers the influence of the market volatility and technological market index. …”
Get full text

Author Correction: Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy by Anna Galstyan, Janet L. Markman, Ekaterina S. Shatalova, Antonella Chiechi, Alan J. Korman, Rameshwar Patil, Dmytro Klymyshyn, Warren G. Tourtellotte, Liron L. Israel, Oliver Braubach, Vladimir A. Ljubimov, Leila A. Mashouf, Arshia Ramesh, Zachary B. Grodzinski, Manuel L. Penichet, Keith L. Black, Eggehard Holler, Tao Sun, Hui Ding, Alexander V. Ljubimov, Julia Y. Ljubimova

Get full text

Pharmacokinetics and tolerability of apremilast in healthy Korean adult men by Ki Young Huh, Yewon Choi, Jim Nissel, Maria Palmisano, Xiaomin Wang, Liangang Liu, Francisco Ramirez‐Valle, Howard Lee

Get full text

Methodological Considerations in Development of UV Imaging for Characterization of Intra-Tumoral Injectables Using cAMP as a Model Substance by Frederik Bock, Johan Peter Bøtker, Susan Weng Larsen, Xujin Lu, Jesper Østergaard

Get full text

Exploring the Role of Surfactants in Enhancing Drug Release from Amorphous Solid Dispersions at Higher Drug Loadings by Sugandha Saboo, Pradnya Bapat, Dana E. Moseson, Umesh S. Kestur, Lynne S. Taylor

Get full text

Current approaches to evaluate the function of cytotoxic T-cells in non-human primates by Cris Kamperschroer, Brendon Frank, Caroline Genell, Hervé Lebrec, Shermaine Mitchell-Ryan, Brigitte Molinier, Courtni Newsome, Marie-Soleil Piche, Daniel Weinstock, Mark Collinge, Wendy Freebern, Daniel Rubio

Get full text

Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study by Alexis Ogdie, Yomei Shaw, Michele Almonte, Ervant J. Maksabedian Hernandez, Bradley Stolshek, Kaleb Michaud

Get full text

HTA und aktuelle Herausforderungen: Harmonisierung, Real World Data und Surrogatparameter by Rüther, Alric, Herrmann, Kirsten H., Hebborn, Ansgar, Perleth, Matthias, Schwarzer, Ruth, Schürmann, Christoph, Sieben, Wiebke, Gillhaus, Johanna, Goertz, Ralf, Jeratsch, Ulli, Leverkus, Friedhelm, Schramm, Wendelin

Get full text

A Metabolomics Approach to Increasing Chinese Hamster Ovary (CHO) Cell Productivity by Grace Yao, Kathryn Aron, Michael Borys, Zhengjian Li, Girish Pendse, Kyongbum Lee

Get full text

Pricing in the Market for Anticancer Drugs by Howard, David H., Bach, Peter B., Berndt, Ernst R., Conti, Rena M.

“…In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab— brand name Yervoy—at $120,000 for a course of therapy. …”
Get full text
Get full text

A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance by Mohd Anisul, Jarrod Shilts, Jeremy Schwartzentruber, James Hayhurst, Annalisa Buniello, Elmutaz Shaikho Elhaj Mohammed, Jie Zheng, Michael Holmes, David Ochoa, Miguel Carmona, Joseph Maranville, Tom R Gaunt, Valur Emilsson, Vilmundur Gudnason, Ellen M McDonagh, Gavin J Wright, Maya Ghoussaini, Ian Dunham

Get full text

Telomerase Reverse Transcriptase Increases Proliferation and Lifespan of Human NK Cells without Immortalization by Maria A. Streltsova, Maria O. Ustiuzhanina, Eugene V. Barsov, Sofya A. Kust, Rodion A. Velichinskii, Elena I. Kovalenko

Get full text

Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper by Karelle Ménochet, Hongbin Yu, Bonnie Wang, Jay Tibbitts, Cheng-Pang Hsu, Amrita V. Kamath, Wolfgang F. Richter, Andreas Baumann

Get full text

A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma by Dena H. Jaffe, Joseph Gricar, Marc DeCongelio, deMauri S. Mackie

Get full text

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole by Patel C, Li L, Girgis S, Kornhauser D, Frevert E, Boulton D

“…Chirag G Patel, Li Li, Suzette Girgis, David M Kornhauser, Ernest U Frevert, David W BoultonBristol-Myers Squibb, Princeton, NJ, USABackground: Many medicines, including several cholesterol-lowering agents (eg, lovastatin, simvastatin), antihypertensives (eg, diltiazem, nifedipine, verapamil), and antifungals (eg, ketoconazole) are metabolized by and/or inhibit the cytochrome P450 (CYP) 3A4 metabolic pathway. …”
Get full text

Place of death and other factors associated with unnatural mortality in patients with serious mental disorders: population-based retrospective cohort study by Rebecca Wilson, Fiona Gaughran, Tara Whitburn, Irene J. Higginson, Wei Gao

“…Unnatural causes of death were higher in younger patients with non-schizophrenia spectrum disorder diagnoses.Declaration of interestF.G. has received support or honoraria for CME, advisory work and lectures from Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Roche, and Sunovion, and has a family member with professional links to Lilly and GSK, including shares.…”
Get full text

Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices by Ewen E, Zhang Z, Simon TA, Kolm P, Liu X, Weintraub WS

“…Edward Ewen,1 Zugui Zhang,1 Teresa A Simon,2 Paul Kolm,1 Xianchen Liu,3,4 William S Weintraub11Christiana Care Health System, Newark, DE, USA; 2Bristol-Myers Squibb, Princeton, NJ, USA; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4Pfizer, Groton, CT, USABackground: Warfarin is recommended for stroke prevention in high-risk patients with atrial fibrillation. …”
Get full text

Development and equivalence of new faces for inclusion in the Childhood Asthma Control Test (C-ACT) response scale by Kate Sully, Nicola Bonner, Helena Bradley, Robyn von Maltzahn, Rob Arbuckle, Louise Walker-Nthenda, Aoife Mahon, Brandon Becker, Louise O’Hara, Katherine B. Bevans, Mark Kosinski, Robert S. Zeiger, Ross Mackenzie, Linda Nelsen

Get full text